Tamsulosin for the treatment of chronic abacterial prostatitis.
- Author:
Xiao-Song CHEN
1
;
Zhang-Qun YE
;
Xiao-Yong ZENG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; therapeutic use; Adult; Chronic Disease; Humans; Male; Middle Aged; Pelvic Pain; drug therapy; etiology; Prostatitis; complications; drug therapy; Receptors, Adrenergic, alpha-1; Sulfonamides; therapeutic use; Treatment Outcome
- From:National Journal of Andrology 2002;8(1):51-53
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVESTo evaluate the efficacy of selective alpha 1A-adrenergic receptor antagonists for the treatment chronic abacterial prostatitis/chronic pelvic pain syndrome (CPPS).
METHODSFrom October 2000 to September 2001, a selective alpha 1A-adrenergic receptor antagonists, tamsulosin, had been used in 43 patients with CPPS for four weeks. 0.2 mg dosage was given daily, and uroflowmetry was followed. Symptom scores were evaluated by the NIH-chronic prostatitis symptom index (NIH-CPSI) before and after the treatment.
RESULTSThese patients had a clinically significant response to the treatment of tamsulosin. Of these, thirty two patients (74.5%) responded to one month therapy and had a decrease in NIH-CPSI scores, while maximal urinary flow rate (MFR) and average urinary flow rate (AFR) in patients with poor MFR improved 30.4% and 65.4%, respectively. No severe side effects were observed.
CONCLUSIONSIt is suggested that Tamsulosin, a selective alpha 1A-adrenergic receptor antagonist, is effective in the treatment of CPPS.
